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Splenic lymphocytes from nonimmune  mice (or blood lymphocytes from people) 
can lyse or damage a  variety of target cells,  notably malignant  cells,  in  vitro. This 
reaction has been termed natural killer (NK) activity, because no overt immunization 
is required.  NK activity is  independent  of antibody and complement and does not 
reflect conventional  phagocytic activity.  Numerous  additional  studies  have sharply 
distinguished  NK  cells  from  characteristic  T  lymphocytes,  B  lymphocytes,  and 
macrophages (1-8). 
NK ceils  have received  considerable  attention  because of their  potential  role  in 
resistance  to  malignancy.  Mice  lacking  a  normal  T-cell  system  probably  do  not 
develop an inordinately high incidence of spontaneous tumors  (9,  10).  The case for 
immunologic surveillance against neoplastic growth may therefore rest, in part, upon 
the participation of a non-T-cell population. This hypothetical cell population should 
be  capable  of destroying  very  small  numbers  of nascent  tumor  cells  that  might 
otherwise slip through the T-cell system. One candidate for this non-T-cell set is the 
NK-cell system, in view of experiments that indicate a positive correlation between in 
vitro NK-lytic activity and in vivo resistance to several lymphoid tumors (11-13). 
Despite this association between  NK function  and resistance to tumor growth,  it 
has not  been possible to  directly test whether  NK cells can prevent  in  vivo tumor 
growth.  Such  tests  depend  up6n  the  ability  to  obtain  purified  NK  cells  from 
heterogeneous cell populations. We have established that NK cells express both the 
NK-1- (14) and Ly5-surface components (15), and that antisera that is specific for the 
latter cell-surface component allows highly efficient positive selection of NK cells from 
a  heterogeneous Thyl--cell population.  We demonstrate here that, unlike other sets 
of spleen  ceils  from nonimmune  mice, positively selected  NK cells prevent  in  vivo 
growth of lymphomas. 
Materials and Methods 
Mice.  B6, BALB/c, and A/SN mice were purchased from The Jackson Laboratories, Bar 
Harbor, Maine. B6-Ly5.2 congenic mice were produced by E. A. Boyse at the Sloan-Kettering 
Cancer Center, New York. 
Tumor Cells.  RLdl is a BALB/c radiation-induced leukemia (16) and is carried in vitro in 
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our laboratory as described previously (14). YAC is a Moloney virus-induced lymphoma of A/ 
J  mice (2) and the ascites form is passaged in vivo in A/J mice in this laboratory. 
Positive Selection of lg + Spleen  Cells.  The Ig* fraction of spleen cells was eluted from Petri 
dishes coated with Ra-mouse Fab, according to the method of Wysocki and Sato (17).  After 
two sequential elutions, the remaining population was 96-100% Ig  + as judged by immunoflu- 
orescence. 
Positive Selection of Ly5  + Cells or Thy l + Cells.  Spleen cells from B6, B6-Ly5.2, BALB/c, or A/ 
J  mice are passed through a nylon-wool column and treated with anti-Thyl.2 (final dilution 1: 
20) and a selected rabbit serum as a source of complement. These cells are washed three times 
and incubated for 30 rain at 4oC with anti-Ly5.1 or normal mouse serum (NMS) (final dilution 
of 1:20)  in the absence of complement. 5 ml of these cells (107/ml) are added to Petri dishes 
(100  ×  20-ram Falcon 3003,  Falcon Labware, Div. of Becton, Dickinson & Co., Oxnord, Calif.) 
coated with a monolayer of sheep erythroeytes (SRBC) conjugated to protein A. Coupling of 
SRBC  to protein A  was performed according to the method of Parrish and Hayward  (18); 
protein A-SRBC monolayers were prepared according to the method of Stulting and Burke 
(19). 
After a  15-min incubation of lymphocytes at 4°C, the plates are gently swirled and incubated 
an additional 15 min at 4°C.  Unbound  (nonadherent) cells are removed by gently aspirating 
the supernate with a  Pasteur pipette. Bound cells are released from the monolayers after the 
addition of 2 ml of distilled water, for 15 s, followed by the addition of 2 ml of 2 N phosphat- 
buffered saline. This procedure lyses SRBC  and permits recovery of the bound lymphocyte 
population. The recovered cell populations (unbound plus bound) represent -~ 80-95% of the 
starting (input) cell population. 
Analysis  of the Specificity of Positive Selection Using Ly5.1 or Thyl.2 Antiserum.  Spleen cells from 
B6  (Ly5.1 +)  mice were  passed  through  nylon wool columns,  treated with  anti-Thyl  +  C, 
washed, and  incubated with anti-Ly5.1  as described above. The nonadherent  and adherent 
fractions of cells obtained after incubation on protein A-coated Petri dishes were incubated at 
37°C for 3 h in RPMI-1640 (Grand Island Biological Co., Grand Island, N. Y.) supplemented 
with  15%  FCS. This 3-h incubation procedure is required to eliminate any mouse immuno- 
globulin bound to lymphocytes during the positive selection procedure. After one additional 
wash,  the cells were then  incubated with either anti-Ly5.1 or NMS  +  C.  Background lysis 
(after incubation with NMS  +  C) was 14-18%. Analysis of the input population (nylon-passed, 
anti-Thyl  +  C-treated cells) indicated that  this population contained  -  15%  Ly5.1 + cells. 
Analysis of the separated populations showed that the nonadherent cell population contained 
<5% Ly5.1 + cells, whereas the adherent fraction contained >80%  (82-87%) Ly5.1 + cells. This 
separation was specific because (a) separation of cells coated with anti-Ly5.1 sera that had been 
absorbed with B6 spleen cells (equal volumes of packed cells and antisera at a  1:5 dilution for 
½ h at 4°C)  did not result in the enrichment of Ly5.1 + cells in the bound population; and (b) 
absorption of anti-Ly5.1 sera with B6-Ly5.2 cells had no effect upon the efficiency of positive 
selection. Similar analysis of the specificity of selection using Thy 1.2 antisera indicated that the 
bound population (representing 30-34% of spleen cells) was 95-98% Thyl.2  +. 
Assay for In  Vitro NK Activity.  NK activity was determined according to a modification of a 
previously described protocol (14).  3  ×  104 nlcr-labeled target cells were incubated in RPMI- 
1640 plus 10% fetal calf serum alone or together with different spleen cell populations at 37°C 
in a humidified atmosphere of 95% air, 5% COz. The amount of gamma radioactivity released 
from triplicate cultures after 5 h was determined. Cytotoxicity is expressed as percent specific 
lysis according to the following formula: 
percent lysis =  experimental release -- spontaneous release  ×  100. 
maximal release (freeze thaw) -- spontaneous release 
Measurement  of In  Vivo Tumor  Growth.  8  X  104  RLdl  cells are inoculated  (alone or with 
lymphoid cells) subcutaneously in 0.1 ml using a 28-gauge needle (Sherwood Medical Industries, 
Inc.,  DeLand,  Fla.) beneath  the shaved flanks of syngeneic BALB/c  (400  rads)  mice.  The 
appearance of a white-capped bleb signifies accurate placement, l04 YAC lymphoma cells were 
similarly inoculated into unirradiated syngeneic A/J mice. No growth signifies animals that 
did not develop tumor within 35 d after inoculation. Growth was invariably progressive until 
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FIG.  1.  Enrichment of in vitro NK activity after positive selection with anti-Ly5.1. Percent lysis of 
51Cr-labeled RI.,dl  cells after a 5-h incubation with unselected spleen cells (V'I); Ly5.1- spleen cells 
(I);  Thyl-Ig-Ly5 + cells (O); and Thyl-Ig-Ly5-  cells (0). 
Results 
Enrichment of In Vitro NK Activity after Positive Selection (Fig.  1).  Spleen cell popula- 
tions, depleted of Ly5  + cells, exerted virtually no detectable NK activity. By contrast, 
Ig-Thyl- populations, containing m80%  Ly5  + cells after positive selection, exerted 
substantial  NK  lysis.  This  activity represented  -~  a  four-  to  six-fold  enrichment 
compared  to  unselected  spleen  cells.  Enhanced  NK  activity was  a  result  of the 
enrichment of Ly5  + cells because NK activity was abolished after treatment of these 
cells with anti-Ly5.1 (but not anti-Ly5.2 or NMS)  +  C. 
In  Vivo Activity  of Ly5 + NK Cells (Table I).  Subcutaneous inoculation of 8  ×  104 
RLdl cells into sublethally irradiated (400  rads)  syngeneie BALB/c mice results in 
100% tumor growth within  15  d.  Subcutaneous inoculation of 104  YAC cells into 
unirradiated A/J mice results in  100% tumor growth within 16-18 d. Subcutaneous 
growth of either RLdl or YAC tumor cells was not affected by co-inoculation of (5- 
10  x  106) the following syngeneic (BALB/c or A/J, respectively) lymphocyte popu- 
lations:  (a)  nonimmune spleen ceils;  (b)  nylon-passed spleen cells;  (c)  Thyl ÷ spleen 
cells; (d) Ig  + spleen cells; and (e) Thyt- spleen cells (after treatment with anti-Thyt 
+  c). 
By contrast, spleen cells expressing the Ig-Thyl-Ly5+-surface phenotype (which 
account  for <5%  of the total spleen  cell population)  conferred virtually complete 
protection against the growth of either Rl.z31 or YAC tumor cells.  This protective 
effect was a  result of Ly5  + NK cells because no protective effects were exerted by 
equal numbers of viable Ig-Thy 1- cells that remained after treatment with anti-Ly5.1 
+C. 
Summary 
Relatively large numbers of nonimmune spleen cells do not protect against the local 
growth of two lymphomas. However, this heterogeneous population of splenic lym- 
phocytes contains a  subset of cells that  efficiently protects  against  in  vivo tumor 
growth. This cell population  (cell-surface phenotype Thyl.2-Ig-Ly5.1  +)  represents 
<5% of the spleen cell population and is responsible for in vitro NK-mediated lysis. 
Although these studies clearly and directly demonstrate that Ly5  + NK cells selected 
from  a  heterogeneous  lymphoid  population  from  nonimmune  mice  can  protect 
syngeneic mice against local in vivo growth of two different types of tumor cells (in M.  KASAI ET AL.  BRIEF DEFINITIVE REPORT 
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Ability  of Different Lymphocyte Sets to Prevent Lymphoma Growth In  Vivo 
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(]ell number 
Spleen cell population  (X  10  ~) 
Tumor incidence* 
Host: BALB/c  A/J 
Tumor: RLdl  YAC 
A None  --  22/22  16/16 
B Unselected  I0  8/8  8/8 
C Nylon-passed cells  5  14/15  15/15 
D Thyl  + cells  5  8/8  8/8 
E Ig  + cells  5  16/16  16/16 
F Thy 1- cells  5  19/22  22/22 
G Thyl- Ig-Ly5  + cells  2  1/12  0/12 
H Group G treated with anti-Ly5.1  +  C  2  7/8  7/8 
* Results of three individual experiments. 
contrast to other lymphocyte sets within the spleen), they do not directly bear upon 
the role of NK cells in immunosurveillance. They do indicate that  highly enriched 
Ig-Thyl-Ly5  ÷ cells, which account for virtually all in vitro NK activity, can retard 
tumor growth in vivo. 
It  is  difficult to ascribe all  anti-tumor surveillance activity to NK cells, because 
they probably do not recirculate freely throughout the various organ systems of the 
body. Perhaps NK ceils may play a  role in prevention of neoplastic growth within 
discrete anatomic compartments where there is rapid differentiation of stem cells to 
mature progeny (e.g., bone marrow, spleen, and portions of the gastrointestinal tract) 
and  may normally act to regulate the growth and  differentiation of non-neoplastic 
stem cells.  Long-term observation of chimeric mice repopulated with bone marrow 
from congenic or mutant  donors expressing very low or very high NK activity may 
help to answer these questions. 
Received  for publication 12 February 1979. 
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